January 27, 2006 – Pfizer won US approval for Exubera, the inhaled form of insulin and a potential blockbuster drug; Pfizer also announced that European authorities recommended Lyrica as a therapy for generalized anxiety disorder in adults; CV Therapeutics won FDA approval for Ranexa, an extended release form of a chronic angina drug; SuperGen will acquire Montigen Pharma, a privately held company that focuses on oncology, for $18 million; INEX Pharma will spin out the company’s targeted immunotherapy assets into a new company; Genzyme said European authorities recommended approval for Myozyme, a treatment for Pompe disease; Chiron granted a non-exclusive license to AVI BioPharma covering patents on antisense therapies for hepatitis C virus; New River Pharma reported the FDA has accepted an application for its ADHD drug; and GenVec presented positive long-term data on TNFerade, a cancer drug. The Centient Biotech 200™ gained 21 points, ending at 3943.21, a rise of .54%. More details...
